^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    TNFRSF8 positive

    i
    Other names: TNFRSF8, TNF Receptor Superfamily Member 8, Tumor Necrosis Factor Receptor Superfamily Member 8, Lymphocyte Activation Antigen CD30, CD30L Receptor, Ki-1 Antigen, D1S166E, CD30, Tumor Necrosis Factor Receptor Superfamily, Member 8, Cytokine Receptor CD30, CD30 Antigen, TNFRSF8, Ki-1
    Entrez ID:
    943
    Related biomarkers:
    Expression
    Others
    3d
    Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides (clinicaltrials.gov)
    P1, N=10, Suspended, University of Alabama at Birmingham | Trial completion date: Jul 2026 --> Jul 2027 | Recruiting --> Suspended | Trial primary completion date: Apr 2026 --> Jun 2027
    Trial completion date • Trial suspension • Trial primary completion date
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 positive
    |
    Adcetris (brentuximab vedotin) • Poteligeo (mogamulizumab-kpkc)
    7d
    Brentuximab vedotin in cutaneous T-Cell lymphoma: emerging evidence and therapeutic insights for CD30-negative and CD30-low disease. (PubMed, Cancer Treat Res Commun)
    BV is a key therapy for CD30-positive CTCL. While real-world experience suggests potential activity in CD30-negative or low disease, prospective trials are needed to define its role in this challenging subgroup.
    Review • Journal
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 positive • TNFRSF8 expression
    |
    Adcetris (brentuximab vedotin)
    8d
    Breast Implant-Associated Anaplastic Large Cell Lymphoma Following Prophylactic Mastectomy & Breast Reconstruction: A Case Report. (PubMed, Acta Chir Belg)
    Current evidence suggests a possible oncogenic interaction between hereditary susceptibility and chronic implant-associated inflammation. Clinicians must maintain vigilance for BIA-ALCL even in prophylactic settings, as early diagnosis and complete surgical excision remain key to favorable outcomes.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    ALK positive • TNFRSF8 positive • ALK negative
    9d
    CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30) (clinicaltrials.gov)
    P1, N=60, Recruiting, Baylor College of Medicine | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial primary completion date
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 positive
    |
    cyclophosphamide • TT11
    11d
    Cutaneous Lymphomas and Lymphoproliferative Disorders Associated With SARS-CoV-2 Vaccination: A Systematic Review. (PubMed, J Skin Cancer)
    Most patients (80%) received the BNT162b2 (Pfizer-BioNTech) vaccine...These findings support indeed the need for continued pharmacovigilance among clinicians, especially in patients with prior or latent lymphoproliferative conditions. Nevertheless, these extremely rare and indolent events should not alter the overall favourable risk-benefit profile of COVID-19 vaccination.
    Review • Journal
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8) • CD4 (CD4 Molecule)
    |
    TNFRSF8 positive
    15d
    Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma (clinicaltrials.gov)
    P=N/A, N=118, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: May 2027 --> Jun 2026 | Trial primary completion date: May 2027 --> Jun 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 positive
    |
    doxorubicin hydrochloride • Adcetris (brentuximab vedotin) • dacarbazine • vinblastine
    15d
    Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in Spain (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
    New trial
    |
    ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    ALK positive • TNFRSF8 positive • ALK negative
    |
    doxorubicin hydrochloride • cyclophosphamide • Adcetris (brentuximab vedotin)
    16d
    Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma (clinicaltrials.gov)
    P=N/A, N=118, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 positive
    |
    doxorubicin hydrochloride • Adcetris (brentuximab vedotin) • dacarbazine • vinblastine
    18d
    Primary Cutaneous Anaplastic Large Cell Lymphoma Mimicking Pyoderma Gangrenosum: An Atypical Presentation and Diagnostic Challenge. (PubMed, Cureus)
    The patient responded partially to cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone (CHOEP) chemotherapy and achieved a complete metabolic response after second-line chemotherapy consisting of dexamethasone, high-dose cytarabine, and carboplatin (DHAC) followed by BEAM-ASCT consolidation. This case highlights diagnostic and therapeutic challenges in atypical presentations of PC-ALCL.
    Journal
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 positive
    |
    carboplatin • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • dexamethasone
    19d
    PLRG-HL05: Efficacy and Tolerability of N-AVD compared to BrECADD in patients with advanced Hodgkin Lymphoma (N-BRAVE) (2026-525263-41-00)
    P2/3, N=370, Not yet recruiting, Polska Grupa Badawcza Chloniakow
    New P2/3 trial
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 positive
    |
    Opdivo (nivolumab) • doxorubicin hydrochloride • etoposide IV • Adcetris (brentuximab vedotin) • dacarbazine • vinblastine
    21d
    Angiocentric Variant of Primary Cutaneous CD30-Positive Anaplastic Large Cell Lymphoma: A Case Report and Literature Review. (PubMed, Cureus)
    The patient responded favorably to electron beam radiotherapy. This case underscores the importance of early biopsy in atypical or treatment-refractory ulcers and highlights the diagnostic relevance of recognizing rare variants such as the angiocentric subtype.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 positive • ALK negative